LONG-TERM SURVIVAL IN SMALL-CELL LUNG-CANCER - POSTTREATMENT CHARACTERISTICS IN PATIENTS SURVIVING 5 TO 18+ YEARS - AN ANALYSIS OF 1,714 CONSECUTIVE PATIENTS

被引:232
作者
LASSEN, U
OSTERLIND, K
HANSEN, M
DOMBERNOWSKY, P
BERGMAN, B
HANSEN, HH
机构
[1] BISPEBJERG HOSP,DEPT MED P,DK-2400 COPENHAGEN,DENMARK
[2] HERLEV UNIV HOSP,DEPT ONCOL,COPENHAGEN,DENMARK
[3] RENSTROMSKA HOSP,DIV PULM,GOTHENBURG,SWEDEN
关键词
D O I
10.1200/JCO.1995.13.5.1215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for greater than or equal to 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981. Patients and Methods: A total 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics. Results: Sixty patients survived longer than 5 years, Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%). Conclusion: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade, Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases. (C) 1995 by American Society of Clinical Oncology.
引用
收藏
页码:1215 / 1220
页数:6
相关论文
共 50 条
  • [1] CHANGES IN MORPHOLOGIC AND BIOCHEMICAL CHARACTERISTICS OF SMALL CELL-CARCINOMA OF THE LUNG - CLINICOPATHOLOGIC STUDY
    ABELOFF, MD
    EGGLESTON, JC
    MENDELSOHN, G
    ETTINGER, DS
    BAYLIN, SB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1979, 66 (05) : 757 - 764
  • [2] LONG-TERM OUTCOME OF SMALL-CELL LUNG-CANCER
    ARMSTRONG, JG
    [J]. CANCER TREATMENT REVIEWS, 1990, 17 (01) : 1 - 13
  • [3] BIOLOGY OF SMALL-CELL LUNG-CANCER
    CARNEY, DN
    [J]. LANCET, 1992, 339 (8797) : 843 - 846
  • [4] PRETREATMENT PROGNOSTIC FACTORS AND SCORING SYSTEM IN 407 SMALL-CELL LUNG-CANCER PATIENTS
    CERNY, T
    BLAIR, V
    ANDERSON, H
    BRAMWELL, V
    THATCHER, N
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (02) : 146 - 149
  • [5] COX DR, 1980, ANAL BINARY DATA
  • [6] FUKUOKA M, 1990, CANCER, V65, P1678, DOI 10.1002/1097-0142(19900415)65:8<1678::AID-CNCR2820650803>3.0.CO
  • [7] 2-N
  • [8] MANAGEMENT OF SMALL-CELL CANCER OF THE LUNG
    HANSEN, HH
    [J]. LANCET, 1992, 339 (8797) : 846 - 849
  • [9] CHEMOTHERAPY OF ADVANCED SMALL-CELL ANAPLASTIC CARCINOMA - SUPERIORITY OF A 4-DRUG COMBINATION TO A 3-DRUG COMBINATION
    HANSEN, HH
    DOMBERNOWSKY, P
    HANSEN, M
    HIRSCH, F
    [J]. ANNALS OF INTERNAL MEDICINE, 1978, 89 (02) : 177 - 181
  • [10] HANSEN HH, 1980, CANCER, V46, P279, DOI 10.1002/1097-0142(19800715)46:2<279::AID-CNCR2820460210>3.0.CO